Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.00.

Several brokerages recently commented on CNTX. Jones Trading started coverage on Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Cantor Fitzgerald began coverage on shares of Context Therapeutics in a research report on Thursday, October 2nd. They issued an “overweight” rating for the company. Wall Street Zen raised shares of Context Therapeutics to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. Finally, Guggenheim initiated coverage on Context Therapeutics in a research note on Thursday, September 18th. They issued a “buy” rating and a $5.00 price objective on the stock.

Context Therapeutics Trading Up 0.6%

Context Therapeutics stock opened at $1.61 on Monday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.00. The company has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $1.01. The company has a market cap of $147.93 million, a P/E ratio of -6.71 and a beta of 1.91.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). On average, equities research analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Hedge Funds Weigh In On Context Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Clear Harbor Asset Management LLC lifted its stake in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock worth $90,000 after buying an additional 35,000 shares during the last quarter. Vanguard Group Inc. lifted its position in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Context Therapeutics during the third quarter worth approximately $100,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.